Related Experiment Video
Updated: Jun 6, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Prescribing in type 2 diabetes: choices and challenges
1NHS Birmingham East and North, Birmingham. jill.hill@benpct.nhs.uk
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)
|December 8, 2010
Summary
Recent advances offer more blood glucose control options for type 2 diabetes. Prescribers must balance safety, cost, and targets when choosing the best medication for individual patients.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Management
Background:
- Recent increase in available glucose-lowering agents for type 2 diabetes.
- National Institute for Health and Clinical Excellence (NICE) provides guidelines for glycaemic control.
- Practitioners have choices at each step of the glycaemic treatment pathway.
Purpose of the Study:
- To discuss the available options for prescribers managing type 2 diabetes.
- To highlight factors influencing medication choice in glycaemic control.
- To support individualized treatment strategies for achieving blood glucose targets.
Main Methods:
- Review of current therapeutic options for type 2 diabetes management.
- Consideration of clinical guidelines and evidence.
- Analysis of factors impacting treatment decisions.
Main Results:
- Multiple classes of agents are available for glycaemic control.
- Prescribing decisions involve balancing efficacy, safety, cost, and patient-specific factors.
- Quality and Outcomes Framework (QOF) targets influence treatment intensification.
Conclusions:
- Individualized patient care is paramount in selecting glucose-lowering medications.
- Prescribers must navigate controversies regarding safety and cost of new therapies.
- Effective management requires a comprehensive approach to achieving glycaemic targets in type 2 diabetes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.